Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 140
- Registration Number
- NCT02304107
- Locations
- ๐ช๐ฌ
BeniSuef University hospitals, BeniSuef, Egypt
๐ช๐ฌCairo University Hospitals, Cairo, Egypt
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT02297438
- Locations
- ๐จ๐ณ
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
๐จ๐ณThe Tumor Hospital of Yunnan Province, Kunming, Yunnan, China
๐จ๐ณThe First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 307
- Registration Number
- NCT02296801
- Locations
- ๐บ๐ธ
Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States
๐บ๐ธHope Women's Cancer Centers, Asheville, North Carolina, United States
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Midwest Fertility Specialists
- Target Recruit Count
- 13
- Registration Number
- NCT02294773
- Locations
- ๐บ๐ธ
Midwest Fertility Specialists- Fort Wayne, Fort Wayne, Indiana, United States
๐บ๐ธMidwest Fertility Specialists, Indianapolis, Indiana, United States
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- ๐บ๐ธ
Woodlands Medical Specialists, Pensacola, Florida, United States
๐บ๐ธHope Cancer Center, Terre Haute, Indiana, United States
๐บ๐ธCenter for Cancer and Blood Disorders, Fort Worth, Texas, United States
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Conditions
- Recurrent Primary Peritoneal CarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Ovarian CarcinomaOvarian Serous Surface Papillary AdenocarcinomaUndifferentiated Ovarian Carcinoma
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT02283658
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- ๐บ๐ธ
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
๐บ๐ธDanbury Hospital SC, Danbury, Connecticut, United States
๐บ๐ธUniversity Of California Los Angeles Dept of Onc, Los Angeles, California, United States
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 334
- Registration Number
- NCT02273973
- Locations
- ๐ฆ๐น
Lkh-Univ. Klinikum Graz; Klinik Fรผr Gynรคkologie, Graz, Austria
๐ง๐ชCliniques Universitaires St-Luc, Bruxelles, Belgium
๐ญ๐บDebreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary
Phase II Study of Everolimus Beyond Progression
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT02269670
- Locations
- ๐บ๐ธ
Emory University Hospital Midtown, Atlanta, Georgia, United States
๐บ๐ธEmory University/Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธEmory Saint Joseph's Hospital, Atlanta, Georgia, United States
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 493
- Registration Number
- NCT02246621
- Locations
- ๐ฆ๐น
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
๐ฏ๐ตShizuoka Cancer Center, Nagaizumi, Shizuoka, Japan
๐บ๐ธIronwood Cancer & Research Centers, Chandler, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.